Kornimate/medical-research-clean huggingface dataset:
the efficacy and safety of hypertonic saline in cardiac surgery patients.

Conditions: Coronary Artery Disease; Edema

Summary: the organ dysfunction following cardiopulmonary bypass (cpb) occurs frequently in cardiac surgery patients. systemic inflammatory response initiated by cpb through releasing of several mediators lead to altered endothelial integrity and in consequence the leakage of proteins and fluids from the intravascular to the interstitial compartment is occurred. increased capillary permeability and decreased colloid osmotic pressure were shown to play a key role for fluid shift and increasing of extravascular water. further tissue edema can result in injury to many organs, including the heart, lungs, brain, kidneys and can lead to adverse outcomes. hypertonic solution creates an osmotic gradient across the cellular membrane, causing a fluid shift from the intracellular and the interstitial spaces of tissue into the intravascular compartment. the purpose of this study is to investigate the efficacy and safety of 7.2% nacl plus 6% hydroxyethyl starch 200/0.5 in patients scheduled for first-time coronary artery bypass grafting with cardiopulmonary bypass.


Eligibility criteria:
inclusion criteria: * patients scheduled for first-time coronary artery bypass grafting with cardiopulmonary bypass exclusion criteria: * age \>70 years * body mass index \ 35 kg/m2 * left ventricular ejection fraction \<40% * myocardial infarction \<6 months before surgery * stroke or transient ischemic attack \<12 months before surgery * diabetes mellitus * glomerular filtration rate \<90 ml/min * emergency surgery * hematocrit \<30%.

Keywords: organ dysfunction hypertonic solution extravascular water cardiopulmonary bypass
clinical approaches to ileal pouch dysfunction

Conditions: Pouchitis

Summary: total proctocolectomy and ileal pouch-anal anastomosis is the surgical treatment of choice for patients with medically refractory ulcerative colitis, ulcerative colitis with dysplasia or cancer, and patients with familial adenomatous polyposis. pouchitis, an inflammatory process of the ileal pouch, is the most common long-term complication. increased stool frequency, abdominal pain, and pelvic discomfort are suggestive of pouchitis, approximately 40% of patients with these symptoms have no or minimal inflammation of the pouch or rectal cuff on endoscopy and histopathology. these patients have a condition resembling irritable bowel syndrome (ibs), which we termed the irritable pouch syndrome (ips). the rationale and feasibility for the proposed study are: 1) ips occurs in a substantial number of patients with ipaa, significantly affecting the quality of life. however, ips is rare in the general population, and is considered an orphan disease. studies such as those we propose can only be conducted in centers with a large number of patients with ipaa. the cleveland clinic has maintained the world's largest ileal pouch registry, with a total of more the 2,500 patients; 2) a series of investigations on the diagnosis and treatment of patients with inflammatory or functional diseases of ips, notably the initial study of ips, have been conducted by our team; 3) in contrast to ibs, the pathophysiology and treatment of ips have not been studied. our hypotheses are that 1) similar to ibs, visceral hypersensitivity may play a role in the pathogenesis of ips, and 2) amitriptyline, a safe and effective agent for patients with ibs, will be more effective than placebo in alleviating symptoms and improving quality of life in patients with ips. the aims of the study are to 1) investigate visceral hypersensitivity using barostat examination of the pouch; 2) conduct a randomized, placebo-controlled clinical trial evaluating the use of amitriptyline in ips.


Eligibility criteria:
inclusion criteria:(must meet all of the following criteria); * having a history of uc and more than 1 year from tpc/ipaa * meet diagnostic criteria of ips, i.e. * symptoms of diarrhea and abdominal pain, with pdai symptoms score \> (range 2-6). * duration of symptoms \> 12 weeks in the preceding 12-months period * pouch endoscopy shows no evidence of inflammation of the ileal pouch and rectal cuff * no antibiotic therapy, aspirin, or non-steriodal anti-inflammatory drugs for 2 weeks prior to entry into the study; no antidepressant and or anti-anxiety medicines for at least 4 weeks. exclusion criteria:(may meet any of the following criteria); * a history of development of side effects from amitriptyline * ipaa for fap; celiac disease; chronic pouchitis; crohn's disease; pouch stricture or anastomotic leak * urinary retention, glaucoma, use of mao inhibitors within past 14 days; acute recovery phase following myocardial infarction; pregnancy * psychiatric disorder, including major depression, which requires medical therapy
methods study to characterize early indicators of weight loss in people

Conditions: Obesity

Summary: methods study to characterize early indicators of weight loss in people.


Eligibility criteria:
inclusion criteria: * subjects \>=18 years of age with bmi \>= 30 and \< 40 kg/m2 exclusion criteria: * females, those with illnesses expected to cause weight loss, those without stable body weight within 3 months of screening.
impact of previous treatment of hcv patients by daads on covid-19 disease frequency and severity

Conditions: Covid19

Summary: evaluate effect of daads on covid-19 disease.

if chronic hcv patients who already received daads are protected against covid 19 and considered to be immune or not and if daads can be used in ttt of covid 19

Eligibility criteria:
inclusion criteria: 1. hcv patient with or without lc. 2. \>18 years old. 3. received daads at 2019. exclusion criteria: 1. combined hcv and hiv infected patients. 2. combined hcv and hbv infected patients. 3. \< 18 years old. 4. pregnant or breast-feeding patients. 5. patients with autoimmune disease. 6. patients with multiorgan failure, active cancer, renal insufficiency. 7. patients received immunosuppressive drugs. 8. immune compromised patients. 9. previous confirmed diagnosis of sars-cov-2 before starting daas.
impact of lung boost device on ventilatory functions and fatigue in patients with interstitial lung diseases

Conditions: Interstitial Lung Disease

Summary: the purpose of this study will be to determine the effect of lung boost exercise on ventilatory functions, fatigue, and physical function capacity in interstitial lung disease patients.

death rates from chronic respiratory diseases have recently increased, largely driven by the rising burden of interstitial lung diseases (ilds) doubling mortality rates over the past 4 decades. pulmonary fibrosis (pf), a form of ild, is characterized by destruction of lung tissue and accounts for the highest increase in mortality rates. according to the global burden of disease study, between the years of 1990 and 2013, there was an 86% increase in ild related years of life lost, and, for the first time, among the top 50 causes of global years of life lost. in patients with ild next to dyspnea, fatigue is expected to be the most prevalent symptom. surprisingly, the prevalence of severe fatigue has been scarcely studied in ild patients and limited information on its associated factors is available. ilds are associated with skeletal muscle dysfunction, worsening exercise capacity, and poor health-related quality of life. so,this study will explore the impact of lung boost on ventilatory function, fatigue and physical function capacity in interstitial lung disease patients and may give a suggestion of therapeutic modality that is easy and applicable groups of patients to decrease the symptoms and improve the quality of life for this patients.

Eligibility criteria:
inclusion criteria: 1. forty female patients have interstitial lung disease . 2. all patients diagnosed as ild on clinical and radiological basis. 3. age will range between 45 to 55 years old . 4. all patients will be with mild hypoxemia range from 90 to 92 oxygen saturation 5. they have interstitial lung disease for at least 3 years ago. 6. stable in medical and hemodynamic state exclusion criteria: 1. cardiovascular (as acute heart failure, unstable angina or recent myocardial infarction) 2. patients with other significant respiratory disorders such as acute infections, pulmonary tuberculosis, chronic obstructive pulmonary disease, asthma, bronchiectasis, lung carcinoma, and pneumothorax. 3. cognitive impairments, history of cerebrovascular accident, active cancer will be excluded. 4. hepatitis, cirrhosis. 5. current treatment for cancer or active infection 6. orthopedic problem.
clinical trial to investigate the pharmacokinetics/pharmacodynamics of sitagliptin

Conditions: Diabetes Mellitus

Summary: the purpose of this study is to investigate the pharmacokinetics and pharmacodynamics of sitagliptin in healthy volunteers.


Eligibility criteria:
inclusion criteria: * healthy male subjects aged 20 - 50 years * a body mass index (bmi) in the range 17-28 kg/m2 * fasting plasma glucose levels in the range 70-110 mg/dl * sufficient ability to understand the nature of the study and any hazards of participating in it * provide written informed consent after being fully informed about the study procedures exclusion criteria: * presence or history of severe adverse reaction to any drug (e.g., sitagliptin) or a history of severe allergic disease * clinically relevant abnormal medical history that could interfere with the objectives of the study * a subject who has the following screening laboratory test results; creatinine clearance (calculated by cockcroft-gault equation) \< 80 ml/min * history of gastrointestinal disease or surgery (except simple appendectomy or repair of hernia), which can influence the absorption of the study drug * a subject whose sbp is over 150 mmhg or below 100 mmhg and dbp is over 95 mmhg or below 65 mmhg * presence or history of drug abuse * participation in other clinical trial within 2 months * use of a prescription medicine, herbal medicine within 2 weeks or over-the-counter medication within 1 week before first dose * blood donation during 2 months or apheresis during 1 month before the study * presence or history of alcohol abuse * users of nicotine-containing substances within the previous three months * use of grapefruit juice, alcohol or smoking during restriction period * subject judged not eligible for study participation by investigator
prospective comparison between te, swe and mre (fullfibro01)

Conditions: Liver Fibrosis

Summary: the main purpose of the present study is to compare the diagnostic performance of three non-invasive stiffness imaging methods (te, swe and mre) in a consecutive cohort of patients with chronic viral c hepatitis or co-infected by hcv+ human human immunodeficiency virus (hiv).

primary endpoint: verify if transient elastography, shear wave elastography, magnetic resonance elastography (mre) get comparable results in the measurement of liver fibrosis secondary endpoint: to evaluate if the level of liver iron overload and steatosis may act as a confounding factor in stiffness measurements by mre. tertiary endpoint: to provide information about the prevalence and grade of steatosis in a consecutive cohort of patients with chronic viral c hepatitis, and to verify if the presence and grade of parenchymal steatosis may affect the correlation between the different non-invasive stiffness imaging modalities. subject: consecutive 100 patients affected by chronic viral c hepatitis or co-infected by hcv+ human human immunodeficiency virus (hiv).

Eligibility criteria:
inclusion criteria: * enrollment of a consecutive cohort of at least 100 patients affected by chronic c virus hepatitis (hcv) or co-infected by hcv+ human immunodeficiency virus (hiv). exclusion criteria: * contraindications to undergo mri examination. impossibility to obtain a valid te measurement (e.g. narrow intercostal spaces; obese patients)

Keywords: hcv hiv liver fibrosis liver iron overload
deproteinised calf blood serum injection for the treatment of acute intracerebral hemorrhage

Conditions: Intracerebral Hemorrhage

Summary: the purpose of this study is to investigate the efficacy and safety of deproteinised calf blood serum injection in alleviating perihematomal edema (phe) and secondary brain injury, as well as neurologic deficits in patients with acute intracerebral hemorrhage (ich).

the study hypothesized that administration of deproteinised calf blood serum injection would alleviate phe and secondary brain injury, thus improving clinical outcomes in patients with ich. the investigators will enroll 60 acute supratentorial ich patients. patients will be assigned randomly to receive either deproteinised calf blood serum injection or placebo treatment, which is blinded to evaluator and patients. all patients in the study will receive standard care treatment and clinical, diagnostic, laboratory, safety, and follow-up evaluations. blood will be drawn and brain mri will be done in different time course. follow-up evaluations, including national institute of health stroke scale(nihss), stroke impact scale , glasgow coma scale ,barthel index score and modified rankin scale assessments, will be done periodically until 90 days after onset.

Eligibility criteria:
inclusion criteria: 1. diagnosis of spontaneous intracerebral hemorrhage(sich) 2. bleeding into deep gray matter (basal ganglionic and thalamus), and the amount of bleeding between 5 and 30 ml; 3. age between 18 and 80 years; 4. presentation within 48 hours of symptom onset, and ncct at 24 hours need to be done in patients presenting within 24 hours of symptom onset in order to exclude hematoma expansion. 5. informed consent by patients or relatives. exclusion criteria: 1. â secondary ich (secondary to trauma, tumor, vascular malformations, ischemic stroke hemorrhagic transformation, etc.); 2. glasgow coma score of 3-8 at admission; 3. parenchymal hemorrhage with ventricle involved; 4. patients with hematoma expansion; . 5. planned surgery within 3 days of symptom onset; 6. incompletely absorbed brain hematoma previously; 7. prestroke modified rankin score(mrs)\>1; 8. patients with hemorrhagic disease or coagulation disorders; 9. patients with severe liver and renal insufficiency;. 10. patients with severe heart failure or other serious systemic diseases; 11. patients with malignant tumors or ongoing anti-tumor therapy; 12. patients with a history of dementia or mental disorders; 13. pregnant or lactating women or those who has a recent fertility plan; 14. any contraindications to mri(such as cardiac pacemakers and other metal implants, claustrophobia); 15. any other neuroprotective has been applied before randomization; 16. terminal patients whose life expectancy \<90 days; 17. patients participating in other clinical trials 30 days prior to randomization.

Keywords: intracerebral hemorrhage perihematomal edema deproteinised calf blood serum injection
home-initiated programme to prepare for operation (hippo) study

Conditions: Anxiety; Fear of Pain; Child Behavior

Summary: a hospital admission and surgical operation commonly triggers great fear and anxiety to young children. this is caused by either lack of knowledge or misconception. although parent and families are often given the task to prepare the child for the oncoming surgery, they often lack information and skill to accomplish this task. although numerous measures such as pre-operative play room, parental companion during induction, distraction therapy have been employed in our institution, this remains to be a challenge for care of young surgical patients. our study proposes to use a "prepare-for-operation" (pfo) bundle to assist our paediatric patients and their families to prepare for surgery. the pfo bundle consists of an informative cartoon video illustrating sequence of events occurring in admission, anesthesia and surgery. the video is also accompanied by activity sheets to encourage patient and family to engage, participate and learn about all these events. they will be instructed to use this pfo bundle before admission. we believe that through this off-site and cost-effective intervention, the fear of children undergoing surgery will be significantly alleviated. the family will also have better satisfaction on hospitalization experience. if proven feasible and effective, this will be a simple intervention tool that can be made accessible to all kkh pediatric patients.

research plan: a prospective assessor-blinded randomized controlled which will recruit 130 pediatric surgical patients aged 4-10 years, undergoing elective operation in kkh. eligible patients will be identified when an operation date has been booked. they will be approached by a research coordinator (rc) who will counsel about the study details, and recruited after consent. randomisaiton will be performed. the subjects will be randomised into group a and group b. group a will undergo standard workflow for elective surgical admissions. group b, in addition to standard workflow, will also receive the pfo bundle which consists of: a cartoon video of about 6 minutes duration illustrating the events occuring during admission, anaesthesia and surgery. video will be given out in dvd and/or with a weblink and a qr code for scanning. the weblink is password protected and is only given to participant and their parents randomised into the video group. instruction will be given to participants and their parents to watch the video 3 days prior to admission sets of activity sheets which have been tailored for different age groups. families would be encouraged to complete activity sheets together.

Eligibility criteria:
inclusion criteria: 1. aged 4-10 years, male or female 2. no prior surgical experience 3. able to communicate clearly, navigate simple technical software, be awake and alert 4. normal development 5. able to read and communicate in english exclusion criteria: 1. abnormal development 2. has had prior surgical experience 3. is participating in another study

Keywords: anxiety pre-operation
end-range mobilization on knee osteoarthritis

Conditions: Osteo Arthritis Knee

Summary: different manual therapy techniques and conservative therapy have been used separately for alleviation of pain and improvement of physical function in patients with knee osteoarthritis (koa). however, no study has reported the effect of combination of these treatment modalities in the management of koa. the aim of this study was to investigate the effect of end-range mobilization added to conservative therapy versus conservative therapy alone on decrease of pain and improvement of functional status in koa.

knee osteoarthritis (koa) is a musculoskeletal condition affecting older people. it is characterized by pain and loss of physical function, which has a negative impact on patients' quality of life. the different international guidelines recommend several non-invasive treatment modalities for the management of koa. conservative therapy including land-based exercises, aquatic exercises, transcutaneous electro neuro stimulation (tens) therapy and balneotherapy has been reported positively in the management of patients with koa (1, 2). manual therapy is also a preferred treatment modality with the aim of alleviation of pain, improvement of joint mobility and therefore the physical condition (1, 2). out of manual therapy techniques, end-range mobilization is a well applied treatment technique in the management of different musculoskeletal conditions (3). till date, the effect of end-range mobilization has not been investigated so far in knee oa. therefore, the aim of this study was to investigate the effect of end-range mobilization added to conservative therapy versus conservative therapy alone on decrease of pain and improvement of functional status in koa.

Eligibility criteria:
inclusion criteria: * koa according to the american college of rheumatology * categorization as end of range problem based on maitland's classification. * at least half year existing and at least 3 pain scores measured with visual analogue scale (vas) during weight-bearing activities * bilateral, moderate-to-severe symptomatic tibiofemoral knee oa with radiographic evidence * at least 90 degree passive knee flexion range * sufficient mental status exclusion criteria: * acute inflammation of the knee * intraarticular injections within the last 3 months * total knee replacement in the opposite side * class ii. obesity (body mass index, bmi\>35kg/m2) * severe degenerative lumbar spine disease (e.g. spondylolisthesis) * systemic inflammatory arthritic or neurological condition * physiotherapy and other balneotherapy attendance within 6 months * contraindication for conservative and manual therapy * unstable heart condition * complex regional pain syndrome

Keywords: musculoskeletal manipulations osteoarthritis, knee conservative treatment
evaluation of the castor single branch stent graft in treatment of acute aortic syndrome

Conditions: Acute Aortic Syndrome

Summary: the objective of this study to evaluate the safety and effectiveness of the castor single branch stent graft for endovascular repair of acute aortic syndrome patients without an inadequate proximal landing zone (\<15mm)

the goal of this observational, ambispective, and multicenter cohort study is to evaluate efficacy and safety of the castor single branch stent graft. 205 patients who received thoracic endovascular aortic repair by meant of the castor single branch stent graft from june 2018 to june 2022 were enrolled in our study. all enrolled patients have an inadequate proximal landing zone (\<15mm) , and they underwent routine follow-up after thoracic endovascular aortic repair at 1-month, 6-months, and 1-year for the following, but not limited to assessment: physical examination, laboratory test and the ct angiography. meanwhile, the enrolled patients will come for continuous follow-up at 2-years, 3-years, and annually to 10-years post-procedure.

Eligibility criteria:
inclusion criteria: * patients with acute stanford type b aortic syndrome who received thoracic endovascular aortic repair by meant of castor single branch stent graft from june 2018 to june 2022 exclusion criteria: * patients with acute type b aortic syndrome with an adequate proximal landing zone (≥15mm) * previous endovascular repair of the aorta * patients with missing data and loss of follow-up
evaluation of the efficacy of manual therapy, therapeutic exercise and the two modalities combined in pain reduction in patients with headache

Conditions: Headache

Summary: the study aims to evaluate which is the best approach for the non-pharmacological treatment of patients with different types of primary headaches (tension-type headache (ttc), trigeminal autonomic headache (tacs) and migraine) or cervicogenic headache by comparing three methods of intervention to control treatment (drug therapy): therapeutic exercise (te), myofascial release + te, and mulligan's manual therapy + te. the efficacy will be evaluated in terms of reduction of headache episodes, pain intensity and its duration.

patients will be evaluated before the start of treatment (t0), at the end of treatment (t1), 3 months after t1 (t2), 6 months after t1 (t3). results will be stratified by gender, age range, and type of headache diagnosed. the 3 non-pharmacological treatment groups will carry out 12 treatment sessions, 3 times a week for 4 weeks, with a duration of 45 minutes each. the control group (ctrl) will carry out pharmacological treatment according to clinical practice, the patients of the ctrl group at the end of the last follow-up evaluation (t3 at 6 months) at their request will be randomized into one of the other three intervention groups.

Eligibility criteria:
inclusion criteria: * patients suffering from primary headache or cervicogenic headache; * age \> 18 years; * signature of the informed consent. exclusion criteria: * upper cervical spine instability; * cervical arterial insufficiency * cervical spine fractures * pregnancies * rheumatoid arthritis * severe cognitive impairment

Keywords: headache rehabilitation manual therapy exercise